Financial Performance - The company's revenue for Q3 2021 was CNY 342,775,244.87, an increase of 11.75% compared to the same period last year, and the year-to-date revenue reached CNY 1,212,681,679.32, up 53.26% year-on-year[3] - The net profit attributable to shareholders for Q3 2021 was CNY 52,379,695.74, representing an 18.33% increase year-on-year, while the year-to-date net profit was CNY 137,713,159.02, a 6.63% increase[3] - The basic earnings per share for Q3 2021 was CNY 0.11, up 22.22% year-on-year, and the diluted earnings per share was also CNY 0.11[4] - Total operating revenue for Q3 2021 reached CNY 1,212,681,679.32, a significant increase of 53.1% compared to CNY 791,257,671.76 in the same period last year[28] - Net profit for Q3 2021 was CNY 133,778,745.44, representing a 6.1% increase from CNY 126,247,006.57 in Q3 2020[29] - The company reported a total comprehensive income of CNY 133,581,372.59 for Q3 2021, up from CNY 126,247,006.57 in Q3 2020[31] Assets and Liabilities - The total assets as of September 30, 2021, were CNY 3,690,908,471.22, a 23.40% increase from the end of the previous year[4] - The total assets of the company as of Q3 2021 amounted to CNY 3,690,908,471.22, compared to CNY 2,991,062,511.44 at the end of Q3 2020, reflecting a growth of 23.4%[28] - The total liabilities increased to CNY 730,914,796.40, up from CNY 141,128,369.42, indicating a substantial rise in financial obligations[27] - The company's equity attributable to shareholders reached CNY 2,910,642,193.37, an increase from CNY 2,804,427,300.38 year-over-year[28] Cash Flow - The company's cash flow from operating activities for the year-to-date was CNY 82,079,575.10, down 63.72% compared to the same period last year[3] - The cash inflow from operating activities totaled CNY 1,150,837,917.77, an increase from CNY 891,367,653.51 in the previous period, representing a growth of approximately 29%[34] - The net cash flow from operating activities was CNY 82,079,575.10, down from CNY 226,249,463.81 in the previous period, indicating a decline of about 64%[34] - Cash outflow for purchasing goods and services was CNY 406,687,308.56, significantly higher than CNY 116,697,811.16 in the previous period[34] - The net cash flow from investing activities was negative at CNY -273,881,865.82, an improvement from CNY -530,418,724.81 in the previous period[35] - The company reported a cash outflow of CNY 36,152,698.13 from financing activities, compared to CNY 31,456,497.57 in the previous period, indicating a higher cash outflow[35] Research and Development - Research and development expenses for the year-to-date were CNY 80,473,801.38, an increase of 88.25% year-on-year, indicating a significant investment in R&D[12] - Research and development expenses increased to CNY 80,473,801.38, up 88.5% from CNY 42,749,087.53 in the previous year[29] Receivables and Liabilities - The company reported an increase in trading financial assets by 68.83% year-to-date, reaching CNY 857,121,656.75, due to increased short-term bank investment[8] - The company's accounts receivable increased by 53.10% year-to-date, amounting to CNY 176,394,679.01, primarily due to receivables from a consolidated subsidiary[8] - The company experienced a significant increase in contract liabilities, which rose by 3778.67% year-to-date to CNY 419,956,003.18, mainly from a consolidated subsidiary[10] Investment Income - The investment income for the year-to-date was CNY 28,692,824.28, a 162.72% increase year-on-year, driven by gains from stock sales and investment returns[13] - Cash received from investment income was 31,645,831.76 CNY, an increase of 19,405,691.44 CNY or 158.54% year-over-year, mainly from the sale of part of the company's holdings in Kang Le Wei Shi stocks and increased financial income[16] - Cash paid for investments was 81,000,000.00 CNY, an increase of 28,848,240.00 CNY or 55.32% year-over-year, indicating increased external investments[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,327, with the largest shareholder holding 49.51% of the shares[20] Other Financial Information - The company received CNY 28,790,292.71 in tax refunds during the period[34] - The company did not adjust the beginning balance sheet items for the new leasing standards as there were no related leasing activities[36] - The third quarter report was not audited[36]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥869,906,434.45, representing a 79.54% increase compared to ¥484,520,630.90 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was ¥85,333,463.28, a slight increase of 0.53% from ¥84,884,458.26 in the previous year[22]. - The net profit after deducting non-recurring gains and losses decreased by 32.89% to ¥51,614,391.46 from ¥76,915,530.41 in the same period last year[22]. - The net cash flow from operating activities was ¥44,859,289.95, down 68.45% from ¥142,201,118.48 in the previous year[22]. - Total assets at the end of the reporting period were ¥3,683,303,396.18, an increase of 23.14% from ¥2,991,062,511.44 at the end of the previous year[22]. - The net assets attributable to shareholders of the listed company were ¥2,858,136,029.58, a 1.92% increase from ¥2,804,427,300.38 at the end of the previous year[22]. - The basic earnings per share remained unchanged at ¥0.18, consistent with the previous year[22]. - The diluted earnings per share also remained unchanged at ¥0.18, consistent with the previous year[22]. - The weighted average return on net assets was 3.01%, a slight decrease from 3.13% in the previous year[22]. - The company reported a total investment income of ¥10,472,034.35, accounting for 11.06% of total profit, primarily from bank financial product returns[59]. Business Operations - The main business focuses on the research, production, and sales of injectable drugs, particularly in the fields of cardiovascular, immune, and neurological diseases[30]. - The company invested in a 45% stake in Beijing Zhongrun Weiye Investment Co., which has become a subsidiary, enhancing its presence in the medical equipment import and export sector[30]. - The primary products include "Saiseng" Thrombolytic Enzyme Injection and "Saisong" Deoxynucleotides Sodium Injection, targeting various medical conditions such as muscular dystrophy and hepatitis[31]. - The company has developed a complete procurement, production, and sales system, ensuring efficient operations[35]. - The company’s subsidiary, Sair Biological, focuses on the development and production of tablets and capsules, with six production lines in operation[32]. - The company has established a comprehensive production chain, allowing it to engage in various dosage forms, including small-volume injections and oral preparations, which mitigates risks associated with raw material price fluctuations[53]. Research and Development - The company’s research and development efforts include new products such as the K193 antibody, which has entered phase 1 clinical trials[34]. - The company is conducting clinical trials for multiple drugs, including Antianjide peptide for cancer treatment, currently in Phase I with progress on five dosage groups[41]. - The company is focusing on the development of new drugs, with several projects in various stages of clinical trials, including K3 for rheumatoid arthritis and K11 for metastatic colorectal cancer[44]. - The company has invested in R&D and established partnerships with research institutions to accelerate product development, including the acquisition of Junyuan Pharmaceutical to expand into the health industry[47]. - The company has developed a proprietary biopharmaceutical purification technology platform, enhancing its capabilities in producing biologically active macromolecules[48]. Market Position and Strategy - The company has achieved over 50% market share in cardiovascular products and immunomodulators, establishing itself as a market leader[40]. - The company aims to expand its market presence through strategic investments and partnerships in the medical and pharmaceutical sectors[30]. - The company is focusing on retaining core personnel to safeguard its R&D capabilities, as talent competition intensifies in the industry[97]. - The company is exploring potential mergers and acquisitions to enhance its market position and expand its product portfolio[196]. Financial Management and Investments - The total amount of raised funds is CNY 1,080,944,700 after deducting issuance costs of CNY 72,855,300[77]. - Cumulative investment of raised funds reached CNY 70,801,000 as of June 30, 2021, with CNY 51,285,710 remaining unused[77]. - The company has established a dedicated account for raised funds to ensure they are used exclusively for investment projects[77]. - The company has not made any significant non-equity investments[73]. - The company has a total of CNY 961,306,871.36 in other financial assets, with a fair value loss of CNY 5,336,402.96[74]. Challenges and Risks - The company faces increased policy risks in the pharmaceutical industry due to ongoing reforms and regulations, impacting market access and operational requirements[95]. - New drug development is a priority, but the company faces risks related to lengthy development cycles and market acceptance, which could impact profitability[97]. - The company anticipates challenges in market expansion and potential price declines due to increased competition and changes in healthcare policies[95]. Corporate Governance and Social Responsibility - The company is committed to social responsibility, integrating it into its business strategy and operations[107]. - Employee rights are protected in compliance with national labor laws, and the company emphasizes a harmonious labor relationship[108]. - The company has established a performance-based compensation system to incentivize employee contributions and align their interests with corporate growth[108].